273 related articles for article (PubMed ID: 7707514)
1. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
Zaiman AL; Lewis AF; Crute BE; Speck NA; Lenz J
J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
Zaiman AL; Lenz J
J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
[TBL] [Abstract][Full Text] [Related]
3. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
Amtoft HW; Sørensen AB; Bareil C; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
[TBL] [Abstract][Full Text] [Related]
4. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
Zaiman AL; Nieves A; Lenz J
J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
[TBL] [Abstract][Full Text] [Related]
5. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
Ethelberg S; Hallberg B; Lovmand J; Schmidt J; Luz A; Grundström T; Pedersen FS
J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
[TBL] [Abstract][Full Text] [Related]
6. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins.
Sun W; Graves BJ; Speck NA
J Virol; 1995 Aug; 69(8):4941-9. PubMed ID: 7609063
[TBL] [Abstract][Full Text] [Related]
8. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
[TBL] [Abstract][Full Text] [Related]
9. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
Martiney MJ; Levy LS; Lenz J
J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
[TBL] [Abstract][Full Text] [Related]
10. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
11. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells.
Nuchprayoon I; Meyers S; Scott LM; Suzow J; Hiebert S; Friedman AD
Mol Cell Biol; 1994 Aug; 14(8):5558-68. PubMed ID: 8035830
[TBL] [Abstract][Full Text] [Related]
12. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.
Boral AL; Okenquist SA; Lenz J
J Virol; 1989 Jan; 63(1):76-84. PubMed ID: 2535754
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.
Wang S; Wang Q; Crute BE; Melnikova IN; Keller SR; Speck NA
Mol Cell Biol; 1993 Jun; 13(6):3324-39. PubMed ID: 8497254
[TBL] [Abstract][Full Text] [Related]
14. Differences in activities of murine retroviral long terminal repeats in cytotoxic T lymphocytes and T-lymphoma cells.
LoSardo JE; Cupelli LA; Short MK; Berman JW; Lenz J
J Virol; 1989 Mar; 63(3):1087-94. PubMed ID: 2644446
[TBL] [Abstract][Full Text] [Related]
15. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
16. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
Lovmand J; Sorensen AB; Schmidt J; Ostergaard M; Luz A; Pedersen FS
J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
[TBL] [Abstract][Full Text] [Related]
17. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
Hallberg B; Schmidt J; Luz A; Pedersen FS; Grundström T
J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
[TBL] [Abstract][Full Text] [Related]
18. Relative importance of elements within the SL3-3 virus enhancer for T-cell specificity.
LoSardo JE; Boral AL; Lenz J
J Virol; 1990 Apr; 64(4):1756-63. PubMed ID: 2157056
[TBL] [Abstract][Full Text] [Related]
19. Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines.
Nielsen AL; Nørby PL; Pedersen FS; Jørgensen P
J Virol; 1996 Sep; 70(9):5893-901. PubMed ID: 8709209
[TBL] [Abstract][Full Text] [Related]
20. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness.
Celander D; Hsu BL; Haseltine WA
J Virol; 1988 Apr; 62(4):1314-22. PubMed ID: 2831392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
